MedPacto, Inc. 235980

KRX · South Korea · Health Technology

KRW 2,970.00-70.00 (-2.30%)

Market closed· Oct 2, 2026, 6:30 AM UTC· KRW · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

MedPacto, Inc. 235980

KRX · South Korea · Health Technology

KRW 2,970.00-70.00 (-2.30%)

Market closed· Oct 2, 2026, 6:30 AM UTC· KRW · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-45.90% · 6MFull-screen chart

Open KRW 3,015.00High KRW 3,115.00Low KRW 2,965.00Close KRW 2,970.00Volume 64.18K

Oct 2, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: KRW 3,040.00
Day range: KRW 2,965.00 – KRW 3,115.00
52-week range: KRW 2,235.00 – KRW 8,650.00
Volume: 64.18K
Market cap: KRW 104.20B
Avg. volume (1Y): 437.76K

Performance

1 week

+3.85%

1 month

+5.32%

3 months

-1.33%

6 months

-44.80%

Year to date

-55.54%

1 year

-28.35%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Pharmaceuticals: Major
Country: South Korea
Exchange: KRX
Shares outstanding: 34.28M
Employees: 54
ISIN: KR7235980000
Beta: 0.21

Technical view

Mixed

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceSep 03, 2026

Osteosarcoma Market is Set to Rise by 2036 as 8 Emerging Therapies Set to Drive Future Growth | DelveInsight

Osteosarcoma management generally relies on a multimodal treatment strategy that integrates surgery with chemotherapy and, in selected cases, radiotherapy. According to the NCCN Guidelines, commonly recommended chemotherapeutic agents include methotrexate, doxorubicin, cisplatin, and ifosfamide. For patients with relapsed, refractory, or metastatic osteosarcoma, second-line options recommended by the NCCN include high-dose ifosfamide, etoposide, regorafenib, sorafenib, radium-223 dichloride, and

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.